Pandemic Leads to Delays in Crucial Early Cancer Screening Tests
Clayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
Related Articles
Sanjay Juneja: ‘When There Is a Need and You Can, You Should’
In the interview with Targeted Oncology, Sanjay K. Juneja, MD, 2024 Oncology Icons honoree, discusses the transformative power of collaboration, technology, and compassionate care in…
Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL
A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field.
Axatilimab Trial Results
Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.
FDA Approves Nogapendekin Alfa for BCG-Unresponsive NMIBC Carcinoma In Situ
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after…
CAR T and Bispecifics Take Center Stage in New Myeloma Trials
Adam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.
Improving BPDCN Recognition and Diagnosis
Dr. Schiller will discuss the red flag symptoms that increase suspicion of BPDCN, the process for diagnosis, and any challenges with differential diagnosis. Dr. Schiller…
FDA Grants Ziftomenib Breakthrough Therapy Designation in NPM1-Mutant AML
This breakthrough therapy designation of ziftomenib marks the first of its kinds in NPM1-mutant acute myeloid leukemia.
Optimizing Cellular Therapy Programs for Community Practices
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory…